



Conference Agenda

(All times shown as CET)

Day 1: Tuesday, November 9

08:00-08:15am, CET	Welcome and Logistics	Franz-Werner Haas (CEO CureVac)
08:15-09:20am, CET	Session I: mRNA vaccine products / product candidates	Chair: Norbert Pardi
08:15-08:20am, CET	Introduction of Session I	Chair
08:20-08:40am, CET	Next generation mRNA vaccine provides robust protection against SARS-CoV-2 challenge in preclinical models	Susanne Rauch
08:40-09:00am, CET	mRNA-1273 and the next generation of Moderna vaccines	Cesar Sanz Rodriguez
09:00-09:20am, CET	Liposomally formulated mRNA for cancer immune therapy (no live Q&A)	Türeci Özlem
09:20 - 10:25am, CET	Session II: Delivery	Chair: Patrick Baumhof & Mustafa Diken
09:20 - 09:25am, CET	Introduction of Session II	Chair
09:25-09:45am, CET	mRNA-LNP applications for acute and chronic liver diseases	Valerie Gouon-Evans
09:45-10:05am, CET	RNA Delivery Beyond the Liver: from Gene Silencing to Gene Editing	Dan Peer
10:05-10:25am, CET	Lipid nanoparticles for in utero mRNA delivery	Michael J. Mitchell
10:25-10:40am, CET	Coffee Break	
10:40-12:10am, CET	Session II: Delivery	Chair: Patrick Baumhof & Mustafa Diken
10:40-10:55am, CET	Peptide Based Nanoparticle-platform for targeted delivery of functional mRNAs (Oral presentation)	Gilles Divita
10:55-11:15am, CET	Exosome therapeutics – engineering nature’s nanoparticle system to deliver mRNA and other drugs	Tony De Fougerolles
11:15-11:35am, CET	Developing mRNA-Based Vaccines and Therapeutics	Pad Chivukula
11:35-11:50am, CET	A versatile toolbox for development of RNA LNP-based vaccines, gene therapies and cell therapies	Martin Rabel
11:50-12:10pm, CET	Influence of lipid nanoparticle delivery chemistry and mRNA modifications on functional protein distribution in mice	Kathryn A. Whitehead
12:10-12:50pm, CET	Lunch Break	
12:50 - 01:15pm, CET	Session III Part 1: RNA Biology	Chair: Katalin Kariko
12:50-12:55pm, CET	Introduction of Session III	Chair
12:55-01:15pm, CET	Nucleoside-modified mRNA mediated modulation of organ-specific lymphatic growth and function	Zoltan Jakus
01:15-02:00pm, CET	CEO Roundtable mRNA Technology – A game changer for the future of global health (no live Q&A)	Stéphane Bancel, Ugur Sahin, Franz-Werner Haas
02:00 - 02:40pm, CET	Session III Part 2: RNA Biology	Chair: Katalin Kariko
02:00-02:20pm, CET	The influence of codon optimality on gene expression	Jeff Collier
02:20-02:40pm, CET	Regulation of mRNA translation and decay	David Bartel
02:40-03:00pm, CET	Coffee Break	

03:00-04:45pm, CET	Session IV: Gene Editing	Chair: Melissa Moore
03:00-03:05pm, CET	Introduction of Session IV	Chair
03:05-03:25pm, CET	Writing DNA with RNA	Cecilia Cotta-Ramusino
03:25-03:45pm, CET	Advances in CRISPR/Cas9 Therapeutic Genome Editing for In Vivo and Ex Vivo Applications (no live Q&A)	Laura Sepp-Lorenzino
03:45-04:05pm, CET	Chemo-enzymatic modifications for altering translational and immunogenic properties of mRNA	Andrea Rentmeister
04:05-04:25pm, CET	Harnessing RNA endonucleases to control gene outputs	Jeremy E. Wilusz
04:25-04:40pm, CET	Correcting metabolic liver diseases by in vivo base editing (Oral presentation)	Gerald Schwank
04:40-04:45pm, CET	Concluding Remarks Day 1	Igor Splawski

Day 2: Wednesday, November 10

08:00-09:00am, CET	Keynote Lecture: The history of mRNA development for therapy	Katalin Kariko
---------------------------	---	-----------------------

09:00-11:10am, CET	Session V: Therapeutics	Chair: Patrick Baumhof & Mathias Vormehr
09:00-09:05am, CET	Introduction of Session V	Chair
09:05-09:25am, CET	Nucleoside-Modified Autoantigen-Encoding mRNA-Vaccine as a Novel Approach for Antigen-Specific Tolerance Induction in Autoimmunity	Christina Krienke
09:25-09:45am, CET	Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents	Philip J. Santangelo
09:45-10:05am, CET	Tumor specific enzyme assisted chemotherapy - a novel approach to specifically eradicate malignant resistant cells	Mikael Björnstedt

10:05-10:20am, CET	Coffee Break	
---------------------------	---------------------	--

10:20-10:40am, CET	Combining antibody and RNA-encoded Interleukin-2 overcomes resistance in MHC class I-deficient cancer	Jan Beck
10:40-10:55am, CET	Regeneration of muscle tissue and function in Stress Urinary Incontinence using engineered RNA (Oral presentation)	Friedrich Metzger
10:55-11:10am, CET	Transient VEGFA expression using VEGFA mRNA-LNPs induces Biliary epithelial cell-driven liver regeneration in mouse models of liver injury (Oral presentation)	Fatima Rizvi

11:10-12:35pm, CET	Session VI: Vaccines	Chair: Norbert Pardi
11:10-11:15am, CET	Introduction of Session VI	Chair
11:15-11:35am, CET	Cancer vaccines candidates based on optimised mRNA-LNP formulations tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells	Stefaan De Koker
11:35-11:55am, CET	IL-1 family members as key regulators of the inflammatory response to RNA vaccines (no live Q&A)	Siri Tahtinen
11:55-12:15pm, CET	Immune responses to SARS-CoV-2 mRNA vaccines in human lymph nodes	Michela Locci
12:15-12:35pm, CET	A VLP-mRNA platform for HIV-1 vaccine development	Paolo Lusso

12:35-01:25pm, CET	Lunch Break	
---------------------------	--------------------	--

01:25-02:45pm, CET	Session VII: Circ RNA	Chair: Igor Splawski
01:25-01:30pm, CET	Introduction of Session VII	Chair
01:30-01:50pm, CET	Harnessing circular RNA biology	Howard Chang
01:50-02:10pm, CET	Engineering Circular RNA Therapeutics	Aravind Asokan
02:10-02:30pm, CET	The therapeutic potential of orna Therapeutics	Thomas Barnes
02:30-02:45pm, CET	Small circular RNA vaccine (Oral presentation)	Guizhi Zhu

02:45-03:05pm, CET	Coffee Break	
---------------------------	---------------------	--

03:05-04:10pm, CET	Session VIII: Manufacturing of mRNA based therapeutics	Chair: Patrick Baumhof
03:05-03:10pm, CET	Introduction of Session VIII	Chair
03:10-03:25pm, CET	Room to grow - strategies to scale up mRNA manufacturing	Katarina Stenklo
03:25-03:40pm, CET	mRNA-LNP Clinical Translation: Preclinical & CMC Considerations	Thomas Madden
03:40-03:55pm, CET	Strategies and considerations for mRNA manufacturing	Laurens Vergauwen
03:55-04:10pm, CET	An engineered T7 RNA polymerase that generates immune-silent mRNA (Oral presentation)	Athanasios Dousis

04:10-04:30pm, CET	Closing and passing of the baton	CureVac to Moderna
---------------------------	---	---------------------------